Cristian Udovicich
@cristian_udo
Radiation Oncologist GenesisCare @Melbourne 🇦🇺 l Former Clinical Fellow @Sunnybrook 🇨🇦 & @PeterMacRadOnc
Thrilled to complete my first year of fellowship! 🙌 Immense gratitude to all my mentors, especially @DrAndrewLoblaw for shaping me into a better RadOnc. Honored to meet future RadOnc stars! 🌟
🧠💥 Pre-op SRS for brain mets is gaining traction. But must we resect 1–3 days after? 🤔 We ran a small feasibility trial. Biological rationale: keeping the irradiated tumor in situ longer may allow immune responses within the tumor to develop🕒 link.springer.com/article/10.100…
👏🏽👏🏽👏🏽 agree! it’s time to retire the “toxicity” moniker #radonc. We are stuck in the past!!!! @sueyom @NehaVapiwala
It is beautiful to see a fellow Penn alumn use the word "Safety" in the title of a #radonc publication. Kudos to Dr. Yeboa and colleagues for sending a positive message about stereotactic radiation therapy! @sueyom @NehaVapiwala pubmed.ncbi.nlm.nih.gov/40531511/
Also take note of the new phase 3 pharma destiny trial - primary endpoint is TNTT…clinicaltrials.gov/study/NCT05950… so pharma are interested in measures like this
First study I’m aware of that integrates PSMA & MRI to define DIL and then treats DIL, prostate and pelvis all in 5 SBRT treatments. Should we have called it Super-FLAME?
ARGOS-CLIMBER trial Ph 1/II trial PSMA PET + MRI guided Boost Unfavourable Int / High + Very High Risk Ca Prostate SABR Protcol N=50 Preliminary 6 m toxicity data: single acute grade 3 gastrointestinal (GI) toxicity of diarrhea and a single late grade 4 GI toxicity of bleeding
Also brachy vs EBRT, n=710, phase 3 international RCT @CDNCancerTrials PR24
For people who say RCTs can’t be done for technology and devices, and we should just use them because we can use them…once again another large trial evaluating proton beam enrolled. Multiple proton beam trials negative, multiple positive, many maturing. Without trials we would…
@RDC13ro does it again! @RSNA Resident and Fellow Roentgen Research Award for his work identifying favourable intermediate patients where #ActiveSurveillance is safe. N=1699, mFU 10.3y 🟰 freedom from Mets for men with GG1 or GG2 with APP4 <5% @UofTDRO @SahgalArjun @ldawsonmd
🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…
- 15 pts - Median SRS-to-surgery: 8 days - No earlier surgery for growth / oedema - No Grade >2 AEs - No issues with histopath diagnosis - Interestingly, the only BrM failure at 13.8m f/u had a 0-day SRS-to-surgery interval - Lab analyses to follow! @PeterMacRadOnc
Happy to co author this work which looks at patient selection and outcomes following local treatments for lung mets. Check it out! Open access
Our work on AI prediction of Radiation induced toxicity in lung cancers is out! Available via open access
Thank you to @IJROBP for giving @StasLazarev and I the opportunity to contribute to the most recent Gray Zone case “The INDIGO Illusion: The Evidence Still Supports Chemoradiation Therapy in Patients with Low-Grade Glioma” redjournal.org/article/S0360-…
Fantastic Grey Zone topic for June of 2025 Which Way to (INDI)GO? Case: 42 yo male with STR of a WHO grade 2 IDH mutant (IDH1 R132H) astrocytoma with loss of ATRX, no 1p/19q codeletion, and no homozygous deletion of CDKN2A/B. redjournal.org/article/S0360-… @IJROBP
1/3 Was lucky to present our ASTuTE trial interim results #ESTRO25 in Vienna Q: How does the @ArteraAI prostate test influence shared ST-ADT decision making - 200 patients, across 28 Australian centers (@Genesis_Care) - 150 UIR and 50 FIR prostate cancer - Only 15% biomarker +ve
@DMoorePalhares, @drhsoli, @SahgalArjun, @Sunnybrook et al discuss temporal ADC changes during chemoradiation: An imaging biomarker for tumor response monitoring and spatial recurrence prediction in glioblastoma. Read about it in the #RedJournal: tinyurl.com/redsnbrk
🚀 New in @JCO_ASCO - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048
Active Surveillance for Favorable intermediate risk prostate cancer. Safe option for select patients. Data presented on #ESTRO25 @DrAndrewLoblaw @dr_vesi
🔥⚡️🚀 First prospective comparison of SBRT vs HDR-BT in prostate cancer (SHERBET study): SBRT shows superior long-term efficacy & lower BCF. Two-fraction HDR-BT w/o ADT? Only in trials for intermediate-risk pts. Great work from Sunnybrook team! #RadOnc #GU25 @DrAndrewLoblaw
📢data from SHERBET metà analysis: SBRT has excellent long-term efficacy with significantly decreased BCF compared to HDR-BT. #ESTRO25 ,@ESTRO_RT ,@DrAndrewLoblaw
Surprising data from Sunnybrook @DrAndrewLoblaw for higher BCR with HDR mono vs sbrt - controversy enough to crash the slides.